AKBA — Akebia Therapeutics Share News
0.000.00%
Last trade - 00:00- $305.81m
- $337.17m
- $236.20m
Brief: Akebia Therapeutics And US Renal Care Sign Commercial Supply Contract To Enable Access To Vafseo
Brief: Akebia Therapeutics And U.S. Renal Care Initiate The Voice Trial Of Vafseo (Vadadustat) For Patients On Dialysis
Akebia Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Akebia Therapeutics Provides Update On Continued Momentum Of Commercial Launch Of Vafseo® (Vadadustat) Tablets
Brief: Akebia Therapeutics Appoints Erik Ostrowski As Chief Financial Officer And Chief Business Officer
Akebia Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Akebia Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Akebia Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Akebia Therapeutics Says Term Of Supply Agreement Extended For An Additional Five Years And Expires On April 2 2029
U.S. RESEARCH ROUNDUP-Braze, Gulfport Energy, Maplebear
U.S. STOCKS ON THE MOVE-Gold miners, B Riley, Xilio Therapeutics
U.S. STOCKS ON THE MOVE-Crypto stocks, Akebia Therapeutics, Sprinklr
Akebia Therapeutics rises after U.S. FDA approves anemia drug
U.S. FDA approves Akebia's anemia drug (updated)
U.S. FDA approves Akebia's anemia drug
Brief: Akebia Therapeutics CFO Ellen Snow To Step Down
Akebia Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Akebia Secures $55 Million Term Loan Financing
Brief: Akebia Therapeutics Announces Appointment Of Nicholas Grund As Chief Commercial Officer